Skip to main content
Erschienen in: Cellular Oncology 3/2015

01.06.2015 | Original Paper

Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells

verfasst von: Zeynep Birsu Cincin, Miray Unlu, Bayram Kiran, Elif Sinem Bireller, Yusuf Baran, Bedia Cakmakoglu

Erschienen in: Cellular Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hesperidin, a glycoside flavonoid, is thought to act as an anti-cancer agent, since it has been found to exhibit both pro-apoptotic and anti-proliferative effects in several cancer cell types. The mechanisms underlying hesperidin-induced growth arrest and apoptosis are, however, not well understood. Here, we aimed to investigate the anti-proliferative and apoptotic effects of hesperidin on non-small cell lung cancer (NSCLC) cells and to investigate the mechanisms involved.

Methods

The anti-proliferative and apoptotic effects of hesperidin on two NSCLC-derived cell lines, A549 and NCI-H358, were determined using a WST-1 colorimetric assay, a LDH cytotoxicity assay, a Cell Death Detection assay, an AnnexinV-FITC assay, a caspase-3 assay and a JC-1 assay, respectively, all in a time- and dose-dependent manner. As a control, non-cancerous MRC-5 lung fibroblasts were included. Changes in whole genome gene expression profiles were assessed using an Illumina Human HT-12v4 beadchip microarray platform, and subsequent data analyses were performed using an Illumina Genome Studio and Ingenuity Pathway Analyser (IPA).

Results

We found that after hesperidin treatment, A549 and NCI-H358 cells exhibited decreasing cell proliferation and increasing caspase-3 and other apoptosis-related activities, in conjunction with decreasing mitochondrial membrane potential activities, in a dose- and time-dependent manner. Through a GO analysis, by which changes in gene expression profiles were compared, we found that the FGF and NF-κB signal transduction pathways were most significantly affected in the hesperidin treated NCI-H358 and A549 NSCLC cells.

Conclusions

Our results indicate that hesperidin elicits an in vitro growth inhibitory effect on NSCLC cells by modulating immune response-related pathways that affect apoptosis. When confirmed in vivo, hesperidin may serve as a novel anti-proliferative agent for non-small cell lung cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat W. Pao, N. Girard, New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175–180 (2011)CrossRefPubMed W. Pao, N. Girard, New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175–180 (2011)CrossRefPubMed
3.
Zurück zum Zitat Q. Wu, Y.F. Chen, J. Fu, Q.H. You, S.M. Wang, X. Huang, X.J. Feng, S.H. Zhang, Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell. Oncol. 37, 399–407 (2014)CrossRef Q. Wu, Y.F. Chen, J. Fu, Q.H. You, S.M. Wang, X. Huang, X.J. Feng, S.H. Zhang, Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell. Oncol. 37, 399–407 (2014)CrossRef
4.
Zurück zum Zitat A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological and clinical perspective. Cell. Oncol. 36, 265–275 (2013)CrossRef A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological and clinical perspective. Cell. Oncol. 36, 265–275 (2013)CrossRef
5.
Zurück zum Zitat N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell. Oncol. 36, 277–288 (2013)CrossRef N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell. Oncol. 36, 277–288 (2013)CrossRef
6.
Zurück zum Zitat A. Maier, AL. Peille, V. Vuaroqueaux, M. Lahn. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell. Oncol. 2015 Jan 9. [Epub ahead of print] DOI 10.1007/s13402-014-0210-8 A. Maier, AL. Peille, V. Vuaroqueaux, M. Lahn. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell. Oncol. 2015 Jan 9. [Epub ahead of print] DOI 10.​1007/​s13402-014-0210-8
7.
Zurück zum Zitat P. Ulivi, R. Silvestrini, Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell. Oncol. 36, 439–448 (2013)CrossRef P. Ulivi, R. Silvestrini, Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell. Oncol. 36, 439–448 (2013)CrossRef
8.
Zurück zum Zitat G. Giaccone, Twenty-five years of treating advanced NSCLC: what have we achieved? Ann. Oncol. 15 Suppl 4: iv81–83 (2004) G. Giaccone, Twenty-five years of treating advanced NSCLC: what have we achieved? Ann. Oncol. 15 Suppl 4: iv81–83 (2004)
9.
Zurück zum Zitat J.W. Neal, L.V. Sequist, Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr. Treat. Options in Oncol. 11, 36–44 (2010)CrossRef J.W. Neal, L.V. Sequist, Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr. Treat. Options in Oncol. 11, 36–44 (2010)CrossRef
10.
Zurück zum Zitat R. Sangha, P.N. Lara, P.C. Mack, D.R. Gandara, Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr. Opin. Oncol. 21, 116–123 (2009)CrossRefPubMed R. Sangha, P.N. Lara, P.C. Mack, D.R. Gandara, Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr. Opin. Oncol. 21, 116–123 (2009)CrossRefPubMed
11.
Zurück zum Zitat S. Mateen, K. Raina, R. Agarwal, Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr. Cancer J. 65, 3–11 (2013)CrossRef S. Mateen, K. Raina, R. Agarwal, Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr. Cancer J. 65, 3–11 (2013)CrossRef
12.
Zurück zum Zitat J. Nones, T.C.E. Spohr, F.C. Gomes, Hesperidin, a flavone glycoside, as mediator of neuronal survival. Neurochem. Res. 36, 1776–1784 (2011)CrossRefPubMed J. Nones, T.C.E. Spohr, F.C. Gomes, Hesperidin, a flavone glycoside, as mediator of neuronal survival. Neurochem. Res. 36, 1776–1784 (2011)CrossRefPubMed
13.
Zurück zum Zitat T. Tanaka, R. Takahashi, Flavonoids and asthma. Nutrients 10, 2128–2143 (2013)CrossRef T. Tanaka, R. Takahashi, Flavonoids and asthma. Nutrients 10, 2128–2143 (2013)CrossRef
14.
Zurück zum Zitat J.A. Manthey, K. Grohmann, N. Guthrie, Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr. Med. Chem. 8, 135–153 (2001)CrossRefPubMed J.A. Manthey, K. Grohmann, N. Guthrie, Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr. Med. Chem. 8, 135–153 (2001)CrossRefPubMed
15.
Zurück zum Zitat J. Yu, L. Wang, R.L. Walzem, E.G. Miller, L.M. Pike, B.S. Patil, Antioxidant activity of citrus limonoids, flavonoids, and coumarins. J. Agric. Food Chem. 53, 2009–2014 (2005)CrossRefPubMed J. Yu, L. Wang, R.L. Walzem, E.G. Miller, L.M. Pike, B.S. Patil, Antioxidant activity of citrus limonoids, flavonoids, and coumarins. J. Agric. Food Chem. 53, 2009–2014 (2005)CrossRefPubMed
16.
Zurück zum Zitat S.L. Hwang, P.H. Shih, G.C. Yen, Neuroprotective effects of citrus flavonoids. J. Agric. Food Chem. 60, 877–885 (2012)CrossRefPubMed S.L. Hwang, P.H. Shih, G.C. Yen, Neuroprotective effects of citrus flavonoids. J. Agric. Food Chem. 60, 877–885 (2012)CrossRefPubMed
17.
Zurück zum Zitat E. Meiyanto, A. Hermawan, Anindyajati: natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian. Pac. J. Cancer Prev. 13, 427–1436 (2012)CrossRefPubMed E. Meiyanto, A. Hermawan, Anindyajati: natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian. Pac. J. Cancer Prev. 13, 427–1436 (2012)CrossRefPubMed
18.
Zurück zum Zitat J.A. Manthey, N. Guthrie, Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J. Agric. Food Chem. 50, 5837–5843 (2002)CrossRefPubMed J.A. Manthey, N. Guthrie, Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J. Agric. Food Chem. 50, 5837–5843 (2002)CrossRefPubMed
19.
Zurück zum Zitat G. Saiprasad, P. Chitra, R. Manikandan, G. Sudhandiran, Hesperidin alleviates oxidative stress and downregulates the expressions of proliferative and inflammatory markers in azoxymethane-induced experimental colon carcinogenesis in mice. Inflamm. Res. 62, 425–440 (2013)CrossRefPubMed G. Saiprasad, P. Chitra, R. Manikandan, G. Sudhandiran, Hesperidin alleviates oxidative stress and downregulates the expressions of proliferative and inflammatory markers in azoxymethane-induced experimental colon carcinogenesis in mice. Inflamm. Res. 62, 425–440 (2013)CrossRefPubMed
20.
Zurück zum Zitat O.G. Benavente, J. Castillo, M. Alcaraz, V. Vicente, J.A. Del, A. Ortuno, Beneficial action of Citrus flavonoids on multiple cancer-related biological pathways. Curr. Cancer Drug Targets 7, 795–809 (2007)CrossRef O.G. Benavente, J. Castillo, M. Alcaraz, V. Vicente, J.A. Del, A. Ortuno, Beneficial action of Citrus flavonoids on multiple cancer-related biological pathways. Curr. Cancer Drug Targets 7, 795–809 (2007)CrossRef
21.
Zurück zum Zitat J. Nones, T.C.E. Spohr, F.C. Gomes, Hesperidin, a flavone glycoside, as mediator of neuronal survival. Neurochem. Res. 36, 1776–1784 (2011)CrossRefPubMed J. Nones, T.C.E. Spohr, F.C. Gomes, Hesperidin, a flavone glycoside, as mediator of neuronal survival. Neurochem. Res. 36, 1776–1784 (2011)CrossRefPubMed
22.
Zurück zum Zitat V. Gaur, A. Kumar, Hesperidin pre-treatment attenuates NO-mediated cerebral ischemic reperfusion injury and memory dysfunction. Pharmacol. Rep. 62, 635–648 (2010)CrossRefPubMed V. Gaur, A. Kumar, Hesperidin pre-treatment attenuates NO-mediated cerebral ischemic reperfusion injury and memory dysfunction. Pharmacol. Rep. 62, 635–648 (2010)CrossRefPubMed
23.
Zurück zum Zitat S. Ou, Pharmacological action of hesperidin. Zhong. Yao. Cai. 25, 531–533 (2002)PubMed S. Ou, Pharmacological action of hesperidin. Zhong. Yao. Cai. 25, 531–533 (2002)PubMed
24.
Zurück zum Zitat O. Benavente-Garcia, J. Castillo, Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J. Agric. Food Chem. 56, 6185–6205 (2008)CrossRefPubMed O. Benavente-Garcia, J. Castillo, Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J. Agric. Food Chem. 56, 6185–6205 (2008)CrossRefPubMed
25.
Zurück zum Zitat A. Chanet, D. Milenkovic, C. Manach, A. Mazur, C. Morand, Citrus flavanones: what is their role in cardiovascular protection? J. Agric. Food Chem. 60, 8809–8822 (2012)CrossRefPubMed A. Chanet, D. Milenkovic, C. Manach, A. Mazur, C. Morand, Citrus flavanones: what is their role in cardiovascular protection? J. Agric. Food Chem. 60, 8809–8822 (2012)CrossRefPubMed
26.
Zurück zum Zitat B.D. Sahu, M. Kuncha, G.J. Sindhura, R. Sistla, Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine 20, 453–460 (2013)CrossRefPubMed B.D. Sahu, M. Kuncha, G.J. Sindhura, R. Sistla, Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine 20, 453–460 (2013)CrossRefPubMed
27.
Zurück zum Zitat J.R. Patil, K.N. Chidambara Murthy, G.K. Jayaprakasha, M.B. Chetti, B.S. Patil, Bioactive compounds from Mexican lime [Citrus aurantifolia] juice induce apoptosis in human pancreatic cells. J. Agric. Food Chem 57, 10933–10942 (2009)CrossRefPubMed J.R. Patil, K.N. Chidambara Murthy, G.K. Jayaprakasha, M.B. Chetti, B.S. Patil, Bioactive compounds from Mexican lime [Citrus aurantifolia] juice induce apoptosis in human pancreatic cells. J. Agric. Food Chem 57, 10933–10942 (2009)CrossRefPubMed
28.
Zurück zum Zitat M. Galleano, O. Pechanova, C.G. Fraga, Hypertension, nitric oxide, oxidants, and dietary plant polyphenols. Curr. Pharm. Biotechnol. 11, 837–848 (2010)CrossRefPubMed M. Galleano, O. Pechanova, C.G. Fraga, Hypertension, nitric oxide, oxidants, and dietary plant polyphenols. Curr. Pharm. Biotechnol. 11, 837–848 (2010)CrossRefPubMed
29.
Zurück zum Zitat H.J. Park, M.J. Kim, E. Ha, J.H. Chung, Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4. Phytomedicine 15, 147–151 (2008)CrossRefPubMed H.J. Park, M.J. Kim, E. Ha, J.H. Chung, Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4. Phytomedicine 15, 147–151 (2008)CrossRefPubMed
30.
Zurück zum Zitat A. Ghorban, M. Nazari, M. Jeddi-Tehrani, H. Zand, The citrus flavonoid hesperidin induces p53 and inhibits NF-κB activation in order to trigger apoptosis in NALM-6 cells: involvement of PPARγ-dependent mechanism. Eur. J. Nutr. 51, 39–46 (2012)CrossRef A. Ghorban, M. Nazari, M. Jeddi-Tehrani, H. Zand, The citrus flavonoid hesperidin induces p53 and inhibits NF-κB activation in order to trigger apoptosis in NALM-6 cells: involvement of PPARγ-dependent mechanism. Eur. J. Nutr. 51, 39–46 (2012)CrossRef
31.
Zurück zum Zitat M. Nazari, A. Ghorbani, A. Hekmat-Doost, M. Jeddi-Tehrani, H. Zand, Inactivation of nuclear factor-κB by citrus flavanone hesperidin contributes to apoptosis and chemo-sensitizing effect in Ramos cells. Eur. J. Pharmacol. 650, 526–533 (2011)CrossRefPubMed M. Nazari, A. Ghorbani, A. Hekmat-Doost, M. Jeddi-Tehrani, H. Zand, Inactivation of nuclear factor-κB by citrus flavanone hesperidin contributes to apoptosis and chemo-sensitizing effect in Ramos cells. Eur. J. Pharmacol. 650, 526–533 (2011)CrossRefPubMed
32.
Zurück zum Zitat K. Mohankumar, S. Pajaniradje, S. Sridharan, V.K. Singh, L. Ronsard, A.C. Banerjea, B.C. Selvanesan, M.S. Coumar, L. Periyasamy, R. Rajagopalan, Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways. Cell. Oncol. 37, 439–454 (2014)CrossRef K. Mohankumar, S. Pajaniradje, S. Sridharan, V.K. Singh, L. Ronsard, A.C. Banerjea, B.C. Selvanesan, M.S. Coumar, L. Periyasamy, R. Rajagopalan, Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways. Cell. Oncol. 37, 439–454 (2014)CrossRef
33.
Zurück zum Zitat S. Aranganathan, N. Nalini, Efficacy of the potential chemopreventive agent, hesperetin [citrus flavanone], on 1,2-dimethylhydrazine induced colon carcinogenesis. Food Chem. Toxicol. 47, 2594–2600 (2009)CrossRefPubMed S. Aranganathan, N. Nalini, Efficacy of the potential chemopreventive agent, hesperetin [citrus flavanone], on 1,2-dimethylhydrazine induced colon carcinogenesis. Food Chem. Toxicol. 47, 2594–2600 (2009)CrossRefPubMed
34.
Zurück zum Zitat C.J. Lee, L. Wilson, M.A. Jordan, V. Nguyen, J. Tang, G. Smiyun, Hesperidin suppressed proliferations of both human breast cancer and androgen-dependent prostate cancer cells. Phytother. Res. Suppl 1, S15–S19 (2010)CrossRef C.J. Lee, L. Wilson, M.A. Jordan, V. Nguyen, J. Tang, G. Smiyun, Hesperidin suppressed proliferations of both human breast cancer and androgen-dependent prostate cancer cells. Phytother. Res. Suppl 1, S15–S19 (2010)CrossRef
35.
Zurück zum Zitat G. Saiprasad, P. Chitra, R. Manikandan, G. Sudhandiran, Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis. Eur. J. Cancer 50, 2489–2507 (2014)CrossRefPubMed G. Saiprasad, P. Chitra, R. Manikandan, G. Sudhandiran, Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis. Eur. J. Cancer 50, 2489–2507 (2014)CrossRefPubMed
36.
Zurück zum Zitat S. Yumnam, HS. Park, MK. Kim, A. Nagappan, GE. et al, Hesperidin induces paraptosis like cell death in hepatoblatoma, HepG2 cells: involvement of ERK1/2 MAPK. PLoS One 30;9(6):e101321 (2014) S. Yumnam, HS. Park, MK. Kim, A. Nagappan, GE. et al, Hesperidin induces paraptosis like cell death in hepatoblatoma, HepG2 cells: involvement of ERK1/2 MAPK. PLoS One 30;9(6):e101321 (2014)
Metadaten
Titel
Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells
verfasst von
Zeynep Birsu Cincin
Miray Unlu
Bayram Kiran
Elif Sinem Bireller
Yusuf Baran
Bedia Cakmakoglu
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 3/2015
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-015-0222-z

Weitere Artikel der Ausgabe 3/2015

Cellular Oncology 3/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …